Silence Therapeutics stock closed at $19.58, up 125.58% on…
By Tobi Opeyemi Amure
AI summary of the source article
Merck KGaA has agreed to acquire Silence Therapeutics for $20.00 in cash per American depositary share, valuing the company's equity at approximately $1.3 billion. Silence Therapeutics' stock rose 125.58% to close at $19.58 on October 19, 2026.
Key facts
- Merck KGaA agreed to pay $20.00 in cash per ADS for Silence Therapeutics, representing an equity value of about $1.3 billion.
- Silence Therapeutics shares closed at $19.58 on October 19, 2026, up 125.58% from Friday's close of $8.68 on volume of 71,918,760 shares.
- The transaction is structured as a UK scheme of arrangement targeted for completion in the first quarter of 2027 with no financing condition.
Source excerpt · FinanceFeeds
The obvious reading is that Silence Therapeutics has already been taken out at $20. It has not. Nasdaq's official close on Monday 19 October 2026 was $19.58, up $10.90, or 125.58 percent, from Friday's $8.68. The buyer is Merck KGaA, Darmstadt, Germany (OTC: MKKGY), not Merck & Co., the US drugmaker that uses the ticker MRK. Merck KGaA has agreed to pay $20.00 in cash per American depositary share…